Epigenetic age clocks measure biological age through DNA methylation patterns. These clocks can detect interventions that slow or reverse aging. A blinded crossover trial design can rigorously compare two such interventions: NAD+ precursors and the peptide Vesugen. This article outlines a protocol framework for that comparison. All data presented is sourced from publicly available scientific literature. No personal experience or testimonial is implied.

Define the Research Question and Primary Endpoint

The primary research question asks whether NAD+ or Vesugen reduces epigenetic age more effectively. The primary endpoint is the change in epigenetic age measured by a validated clock. Secondary endpoints include changes in specific methylation sites and safety profiles. The study must specify the clock in advance. Published research shows the Horvath clock and GrimAge clock are widely used. These clocks estimate biological age from DNA methylation data. The choice of clock influences sample size calculations. A pilot study can inform the expected effect size.

Select a Crossover Design with Washout Periods

A crossover design assigns each participant to both interventions in sequence. This design reduces between-subject variability. Each participant serves as their own control. The trial must include a washout period between treatments. The washout duration depends on the biological half-life of the interventions. NAD+ precursors like nicotinamide riboside have short half-lives. Vesugen is a peptide with unknown clearance kinetics. Published research suggests a washout of something like 4-6 weeks may suffice. Longer washout periods reduce carryover effects. The order of treatments is randomized and blinded.

Determine Inclusion and Exclusion Criteria

Participants should be healthy adults aged 40-70 years. This age range shows measurable epigenetic age variation. Exclude individuals with chronic diseases or regular medication use. Exclude those taking supplements that affect NAD+ metabolism. Smoking and heavy alcohol use are exclusion criteria. Baseline epigenetic age must be assessed before enrollment. Participants with extreme baseline values may be excluded. The literature on aging research suggests homogeneous cohorts improve power. Sample size calculations require estimates of within-subject variability. A target of something like 30-50 participants per sequence is common.

Blinding and Randomization Procedures

Blinding prevents bias in outcome assessment. Both interventions must appear identical. NAD+ precursors are typically oral capsules. Vesugen is a peptide often administered via injection. A double-dummy technique can maintain blinding. Each participant receives an active oral dose and placebo injection. Or active injection and placebo oral dose. The sequence is randomized by a third party. Randomization uses a computer-generated list. Allocation concealment is essential. The blinding code is broken only after data analysis. Researchers conducting independent work should follow institutional protocols and ethics review where applicable.

Intervention Dosing and Administration

NAD+ precursor dosing follows published pharmacokinetic data. Nicotinamide riboside doses of something like 300 mg daily are common. Vesugen dosing is less established. Peptide research often uses doses in the neighborhood of 200 mcg. Administration frequency must match typical regimens. NAD+ precursors are given daily. Vesugen may be given every few days. The trial protocol specifies exact doses and schedules. Compliance is monitored through pill counts and injection logs. Blood levels of NAD+ can be measured as a manipulation check. Validating NAD+ quantification methods is critical. A related protocol on validating NAD+ quantification in plasma via LC-MS/MS provides technical guidance.

Epigenetic Age Measurement and Sample Collection

DNA methylation is measured from blood samples. Whole blood or peripheral blood mononuclear cells are common sources. Samples are collected at baseline and end of each treatment period. The timing of sample collection must be standardized. Fasting morning samples reduce variability. DNA extraction and methylation analysis follow established protocols. The Illumina MethylationEPIC array is a standard platform. Data preprocessing includes normalization and quality control. Epigenetic age is calculated using published algorithms. The primary analysis compares within-subject changes. Paired statistical tests are appropriate for crossover data.

Statistical Analysis Plan

The analysis uses a linear mixed model. This model accounts for period effects and carryover. Fixed effects include treatment, period, and sequence. Random effects include subject. The primary contrast is the difference in epigenetic age change between NAD+ and Vesugen. Secondary analyses examine individual clock components. Adjustment for baseline age and sex is pre-specified. Missing data are handled by multiple imputation. Sensitivity analyses test the robustness of findings. The statistical plan is finalized before unblinding. Power calculations assume a moderate effect size. Published research on epigenetic age interventions shows effect sizes of something like 0.5-1.5 years. A sample size of 60 may provide 80% power.

Safety Monitoring and Adverse Event Reporting

Safety is monitored throughout the trial. Adverse events are recorded at each visit. Blood tests monitor liver and kidney function. NAD+ precursors are generally well-tolerated. Vesugen safety data are limited. Any unexpected events trigger a safety review. A data safety monitoring board oversees the trial. Stopping rules are defined in advance. The protocol includes criteria for participant withdrawal. All adverse events are reported to regulatory bodies. The informed consent form describes potential risks. Participants can withdraw at any time.

Limitations and Considerations

The crossover design assumes no carryover effects. This assumption may be violated if interventions have long-lasting effects. The washout period length is based on limited data. Epigenetic clocks have measurement error. Short-term changes may not reflect long-term aging. The trial duration may be too short to detect meaningful changes. Blinding may be compromised if injections cause local reactions. The double-dummy design adds complexity. Generalizability is limited to the studied population. The cost of epigenetic analysis is high. These limitations must be acknowledged in the final report.

Closing Observations

A blinded crossover trial comparing NAD+ and Vesugen can provide rigorous evidence. The protocol framework addresses key design elements. Epigenetic age clocks offer a promising biomarker. Careful planning reduces bias and confounding. The results may inform future aging research. Peptides referenced here are research chemicals. Their use outside of approved clinical settings is not endorsed.